Exo Lab Italia, a biotech startup founded in 2020 and specialised in the research and development of products based on plant exosomes, has closed a Euro 5 million investment round.

The investment is led by Dsm Venturing and CDP Venture Capital SGR, through Fondo Acceleratori and Fondo Italia Venture II - Fondo Imprese Sud, in co-investment with Fondo Linfa, managed by Riello Investimenti SGR, and the Maia Fund, managed by Praesidium.

Our partner Giuliano Lanzavecchia, assisted by junior associate Martina Serbelloni, assisted dsm-firmenich Ventures in all aspects of the transaction.

Share
Corporate communications and press contacts
If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.

Connect with one of our experts